Panacea raises $8.9 million in series D financing

By Elaine Rigoli

Tampa, Fla., June 12 - Panacea Pharmaceuticals, Inc. has closed its series D private placement, raising $8.9 million.

Participants in the round included Konishi Hiroshi; Kenso Kogyo Co., Ltd.; Kyokuto Securities Co., Ltd.; Medikit Co., Ltd.; Mizuho Capital Co., Ltd.; Nomura Research & Advisory Co., Ltd.; Shin Nihon Jitsugyo Co., Ltd.; and Softbank Investment Corp.

Proceeds from this round of investment will be used to advance the diagnostic and therapeutic products within the HAAH oncology program as well as to strengthen the company's pipeline.

Based in Gaithersburg, Md., Panacea uses genomics and proteomics to develop therapeutics and diagnostics for diseases with substantial unmet clinical need.

Issuer:	Panacea Pharmaceuticals, Inc.
Issue:	Series D financing
Amount:	$8.9 million
Investors:	Konishi Hiroshi; Kenso Kogyo Co., Ltd.; Kyokuto Securities Co., Ltd.; Medikit Co., Ltd.; Mizuho Capital Co., Ltd.; Nomura Research & Advisory Co., Ltd.; Shin Nihon Jitsugyo Co., Ltd.; and Softbank Investment Corp.
Announcement date:	June 12

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.